Your session is about to expire
← Back to Search
Non-invasive Ventilation
Standard Therapy for Asthma
N/A
Waitlist Available
Led By Patrick T Wilson, MD
Research Sponsored by Columbia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights
Study Summary
This study is evaluating whether a breathing machine may help reduce asthma symptoms in children.
Eligible Conditions
- Asthma
- Childhood Asthma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ one year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Feasibility of successfully enrolling, randomizing, and completing data collection in 30 participants within one year.
Secondary outcome measures
Difference in Duration of continuous beta-agonist therapy
Difference in Heart Rate
Difference in Oxygen Saturation
+5 moreOther outcome measures
Cumulative Number of Adverse Events
Side effects data
From 2012 Phase 4 trial • 44 Patients • NCT0112933647%
Constipation
33%
Nausea
33%
Neutropenia
27%
Fatigue
27%
Dyspnoea
27%
Vomiting
27%
Diarrhoea
20%
Arthralgia
20%
Oedema peripheral
20%
Myalgia
20%
Neuropathy peripheral
13%
Urinary tract infection
13%
Cough
13%
Upper respiratory tract infection
13%
Bone pain
13%
Asthenia
13%
Mucosal inflammation
13%
Thrombocytopenia
13%
Abdominal pain
13%
Nasopharyngitis
13%
Hypokalaemia
13%
Insomnia
13%
Nasal congestion
13%
Night sweats
13%
Hot flush
7%
Rash
7%
Urine output decreased
7%
Postoperative wound infection
7%
Hypocalcaemia
7%
Radiation skin injury
7%
Tremor
7%
Sleep disorder
7%
Back pain
7%
Sinus headache
7%
Productive cough
7%
Abdominal pain upper
7%
Dysphagia
7%
Anaemia
7%
Vulvovaginal candidiasis
7%
Alopecia
7%
Drug hypersensitivity
7%
Palpitations
7%
Stomatitis
7%
Weight increased
7%
Haemoglobin decreased
7%
Dehydration
7%
Oedema mouth
7%
Rectal haemorrhage
7%
Hyponatraemia
7%
Coagulopathy
7%
Abdominal distension
7%
Leukopenia
7%
Generalised oedema
7%
Deafness
7%
Lip ulceration
7%
Erythema of eyelid
7%
Abdominal discomfort
7%
Chest pain
7%
Jaundice
7%
Acute sinusitis
7%
Cellulitis
7%
Hypoalbuminaemia
7%
Platelet count decreased
7%
Hypochloraemia
7%
Musculoskeletal pain
7%
Pain in jaw
7%
Dizziness
7%
Bladder irritation
7%
Muscular weakness
7%
Headache
7%
Pain in extremity
7%
Wheezing
7%
Joint swelling
7%
Dyspnoea paroxysmal nocturnal
7%
Musculoskeletal chest pain
7%
Dysphonia
7%
Dermatitis contact
7%
Orthopnoea
7%
Dysgeusia
7%
Depression
7%
Oropharyngeal pain
7%
Hyperhidrosis
7%
Palmar-plantar erythrodysaesthesia syndrome
7%
Plantar erythema
7%
Lymphoedema
7%
Skin exfoliation
7%
Hypertension
7%
Flushing
100%
80%
60%
40%
20%
0%
Study treatment Arm
Patients Without Bone Metastases
Patients With Bone Metastases
Trial Design
2Treatment groups
Experimental Treatment
Group I: Standard Therapy plus BPAPExperimental Treatment2 Interventions
Application of BPAP along with standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
Group II: Standard Therapy (Control)Experimental Treatment1 Intervention
Standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
Find a Location
Who is running the clinical trial?
Columbia UniversityLead Sponsor
1,431 Previous Clinical Trials
2,460,831 Total Patients Enrolled
20 Trials studying Asthma
5,119 Patients Enrolled for Asthma
Patrick T Wilson, MDPrincipal InvestigatorColumbia University
1 Previous Clinical Trials
126 Total Patients Enrolled
1 Trials studying Asthma
126 Patients Enrolled for Asthma
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger